<DOC>
	<DOCNO>NCT02967237</DOCNO>
	<brief_summary>Primary Objective : The primary objective describe effect insulin glargine ( U300 ) type 2 diabetes mellitus ( T2DM ) patient uncontrolled current basal insulin therapy eligible basal switching , accord Physician decision , glycated hemoglobin ( HbA1c ) improvement . Secondary Objectives : - Evolution fast plasma glucose - Evolution insulin dose body weight - Hypoglycemia incidence - Safety - Patients satisfaction change insulin HOE901-U300</brief_summary>
	<brief_title>Evaluation Toujeo Insulin Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment</brief_title>
	<detailed_description>The total study duration per patient approximately 28 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetic adult patient treat basal insulin , without oral antidiabetic agent , without glucagonlike peptide1 ( GLP1 ) receptor agonist HbA1c &gt; 7.5 % Exclusion criterion : Patients high dose insulin ( &gt; 1.2 U/kg ) Use prandial insulin Change dose antidiabetic drug within last 8 week Use systemic glucocorticoid least 2 week last 12 week The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>